US4176198A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment
Assignee: William H Rorer Inc
•
Filing: 1977-10-06
•
Granted: 1979-11-27
•
Expires: 1997-10-06
Abstract
Abstract This invention describes a method of treating inflammation in warm blooded animals by topically administering an effective amount of benzylideneaniline or its derivatives.
Inventors
- 👤 George W. Nuss, Jr.
- 👤 Norman J. Santora
- 👤 George H. Douglas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K31/13; A61K31/135; A61K31/21; A61K31/255
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
81 words
A method of treating inflammation in warm-blooded animals comprising the topical administration to said animal of an effective amount of a pharmaceutically-active compound of the formula: ##STR4## where: R is hydrogen or alkyl; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 may be the same or different and are: hydrogen, alkyl, cyano, nitro, amino, haloloweralkoxy, haloloweralkyl, halo, loweralkoxy and hydroxy.
Claim 2
Independent Claim
81 words
A method of treating inflammation in warm-blooded animals comprising the topical administration to said animal of an effective amount of a pharmaceutically-active compound of the formula: ##STR4## where: R is hydrogen or alkyl; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 may be the same or different and are: hydrogen, alkyl, cyano, nitro, amino, haloloweralkoxy, haloloweralkyl, halo, loweralkoxy and hydroxy.
Claim 3
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(o-chlorobenzylidene)-3-chloro-2-methylaniline.
Claim 4
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylidene-p-toluidine.
Claim 5
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is o-hydroxybenzylideneaniline.
Claim 6
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is o-hydroxybenzylidene-α,α,α-trifluorotoluidine.
Claim 7
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylideneaniline.
Claim 8
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylidene-p-ethylaniline.
Claim 9
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is o-hydroxybenzylidene-2-methyl-3-chloroaniline.
Claim 10
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-o-hydroxybenzylidene-2,3-dimethylaniline.
Claim 11
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-m-chlorobenzylidene-p-fluoroaniline.
Claim 12
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylidene-4-chloroaniline.
Claim 13
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-o-hydroxybenzylidene-p-bromoaniline.
Claim 14
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(p-chlorobenzylidene)-p-fluoroaniline.
Claim 15
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-o-chlorobenzylidene-p-fluoroaniline.
Claim 16
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylidene-2-methyl-4-fluoroaniline.
Claim 17
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(p-chlorobenzylidene)-m-fluoroaniline.
Claim 18
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(p-chlorobenzylidene)-m-chloroaniline.
Claim 19
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(o-chlorobenzylidene)-2-methyl-4-chloroaniline.
Claim 20
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(p-chlorobenzylidene)-2-methyl-3-chloroaniline.
Claim 21
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(p-chlorobenzylidene)-2-methyl-4-chloroaniline.
Claim 22
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-p-chlorobenzylidene-4-methylaniline.
Claim 23
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(2,6-dichlorobenzylidene)-p-chloroaniline.
Claim 24
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-benzylidene-o-toluidine.
Claim 25
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(4-chlorobenzylidene)-4-fluoro-2-trifluoromethylaniline.
Claim 26
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(4-bromobenzylidene)-4-fluoro-2-trifluoromethylaniline.
Claim 27
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(4-fluoro)benzylidene-2-trifluoromethylaniline.
Claim 28
Dependent Claim
16 words
The method of topically treating inflammation according to claim 1 where the compound administered is N-(o-chlorobenzylidene)-3-chloroaniline.
References Cited (Backward Citations)
FR1178601A
Cited
US2847473A
Cited
US3247060A
Cited
DE1222042B
Cited
US3279907A
Cited
US3325521A
Cited
US3452059A
Cited
US3968159A
Cited
US3827780A
Cited
GB1409898A
Cited
US3772209A
Cited
US3947587A
Cited
DE2303521A1
Cited
US3862833A
Cited
US3935337A
Cited
US3842120A
Cited
US3993645A
Cited
US3971821A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-11-26 | 1983-05-28 | 1983-11-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-11-26 | 1987-05-28 | 1987-11-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-11-26 | 1991-05-28 | 1991-11-27 | $7700.00 | Window Closed / Lapsed |